Aimgen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-12-2024
- Paid Up Capital ₹ 0.20 M
as on 15-12-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 266.58%
(FY 2020)
- Profit 238.83%
(FY 2020)
- Ebitda 675.38%
(FY 2020)
- Net Worth 23.64%
(FY 2020)
- Total Assets 9.93%
(FY 2020)
About Aimgen Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Jalagam and Mahamood Pasha serve as directors at the Company.
- CIN/LLPIN
U24100TG2016PTC103124
- Company No.
103124
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2016
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aimgen Life Sciences Private Limited offer?
Aimgen Life Sciences Private Limited offers a wide range of products and services, including Company Law & Labour Law Consultants, Statutory Compliance Services, Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Aimgen Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Jalagam  | Managing Director | 05-Feb-2016 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mahamood Pasha | Director | 05-Jan-2022 | Current |
Financial Performance of Aimgen Life Sciences.
Aimgen Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 266.58% increase. The company also saw a substantial improvement in profitability, with a 238.83% increase in profit. The company's net worth Soared by an impressive increase of 23.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aimgen Life Sciences?
In 2020, Aimgen Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Dayman Resorts And Farmhouse Private LimitedActive 3 years 2 months
Manoj Jalagam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aimgen Life Sciences?
Unlock and access historical data on people associated with Aimgen Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aimgen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aimgen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
